Your browser doesn't support javascript.
loading
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez, Silvia F; Chisholm, Sarah; Borger, Darrell; Foster, Rosemary; Rueda, Bo R; Growdon, Whitfield B.
Afiliación
  • Hernandez SF; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
  • Chisholm S; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States.
  • Borger D; Department of Medicine, Cancer Center, Massachusetts General Hospital, Boston, MA, United States.
  • Foster R; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, B
  • Rueda BR; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, B
  • Growdon WB; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, B
Gynecol Oncol ; 141(3): 570-579, 2016 06.
Article en En | MEDLINE | ID: mdl-27017985
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Protocolos de Quimioterapia Combinada Antineoplásica / Cistadenoma Seroso / Receptor ErbB-2 / Sirolimus Límite: Animals / Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Protocolos de Quimioterapia Combinada Antineoplásica / Cistadenoma Seroso / Receptor ErbB-2 / Sirolimus Límite: Animals / Female / Humans Idioma: En Revista: Gynecol Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos